The key COVID-19 findings in nephrology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
33cited sources
16available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY17-28%
Acute kidney injury occurred in hospitalized COVID-19 patients
A meta-analysis reported acute kidney injury incidence of 17-28% among hospitalized patients with COVID-19.
This is a pooled incidence in hospitalized patients, not a treatment effect. Timing, patient characteristics and any mortality result are not available in this summary.
See the evidence
Acute Kidney Injury (Hospitalized)
17-28% Pooled incidence (95% CI: 14.6-25.3%)
Hansrivijit P, Qian C, Boonpheng B, et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020;68(7):1261-1270.
Higher chronic kidney disease stages tracked with severe COVID-19
172%higher relative hazard
Very high stage chronic kidney disease was associated with a 172% higher relative hazard of severe COVID-19 than low stage disease; moderate and high stages also had higher hazards than low stage disease.
These are pre-pandemic chronic kidney disease associations from the C4R study. Study design, population details and the severe COVID-19 definition are not available in this summary. Relative hazard is not an absolute percentage-point difference.
See the evidence
172% higher relative hazard, calculated from HR 2.72. This is not an absolute percentage-point difference.
Severe COVID-19 risk with very high stage CKD (vs low stage)
HR 2.72 95% CI, 1.88–3.92
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
Severe COVID-19 risk with high stage CKD (vs low stage)
HR 2.33 95% CI, 1.77–3.06
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
Severe COVID-19 risk with moderate stage CKD (vs low stage)
HR 1.27 95% CI, 1.03–1.56
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
Chronic kidney disease risk persisted after COVID-19
Chronic kidney disease risk was reported as higher after COVID-19 and persisted beyond 12 months. End-stage kidney disease was also reported as increased.
The population, comparison group and study design are not available in this summary, so the reported relative increases cannot be interpreted as absolute risk differences or causal effects.
See the evidence
Higher risk of chronic kidney disease after COVID-19
35%
Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney Outcomes in Long COVID. J Am Soc Nephrol. 2021;32(11):2851-2862.
More vaccine doses tracked with lower severe COVID-19 hazard
adjusted HR 0.50 per additional vaccine dose
Among adult kidney transplant recipients, the adjusted hazard ratio for severe COVID-19 requiring hospitalization was 0.50 per additional vaccine dose relative to the immediately preceding dose count.
This Australian cohort covered the Delta and Omicron BA.1/BA.2 waves. It reports an adjusted association; further study-design details and absolute hospitalization risks are not available in this summary.
See the evidence
Severe COVID-19 requiring hospitalization among adult kidney transplant recipients during the Delta and Omicron BA.1/BA.2 waves
adjusted HR 0.50 per additional vaccine dose 95% CI: 0.40-0.65
Tharmaraj, Dhakshayini et al.. Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.. Internal medicine journal. 2026.
Early remdesivir tracked with lower all-cause graft loss
47%lower relative hazard
Versus no remdesivir, early remdesivir was associated with a 47% lower relative hazard of 1-year all-cause graft loss, combining graft failure and all-cause mortality.
Adults were kidney transplant recipients with symptomatic COVID-19; remdesivir began within 7 days and was administered for at least 3 consecutive days. Versus no remdesivir, weighted analyses found no clear difference in all-cause mortality or Long COVID; study design is not available in this summary.
See the evidence
47% lower relative hazard, calculated from HR 0.53. This is not an absolute percentage-point difference.
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir initiated within 7 days and administered for at least 3 consecutive days was associated with lower 1-year all-cause graft loss—a composite of graft failure and all-cause mortality—vs no remdesivir after clone-censor-weight adjustment.
HR 0.53 95% CI: 0.31-0.92
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Early remdesivir was not significantly associated with lower all-cause mortality among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
HR 0.51 95% CI: 0.24-1.06
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Early remdesivir was not significantly associated with lower long-COVID risk among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
HR 0.65 95% CI: 0.21-2.05
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Very high chronic kidney disease stage tracked with Long COVID
120%higher relative odds
Very high stage chronic kidney disease was associated with 120% higher relative odds of Long COVID positivity than low stage disease.
The C4R study concerned pre-pandemic kidney disease stage. Its design, population details, follow-up and definition of Long COVID positivity are not available in this summary. Relative odds are not an absolute percentage-point difference.
See the evidence
120% higher relative odds, calculated from OR=2.20. This is not an absolute percentage-point difference.
Long COVID positivity in very high stage CKD (vs low stage)
OR=2.20 95% CI: 1.16–4.18
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
More vaccine doses tracked with lower severe COVID-19 hazard
adjusted HR 0.50 per additional vaccine dose
Among adult kidney transplant recipients, the adjusted hazard ratio for severe COVID-19 requiring hospitalization was 0.50 per additional vaccine dose relative to the immediately preceding dose count.
This Australian cohort covered the Delta and Omicron BA.1/BA.2 waves. It reports an adjusted association; further study-design details and absolute hospitalization risks are not available in this summary.
Study details & original results
Tharmaraj, Dhakshayini et al.. Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.. Internal medicine journal. 2026.
Severe COVID-19 requiring hospitalization among adult kidney transplant recipients during the Delta and Omicron BA.1/BA.2 waves
adjusted HR 0.50 per additional vaccine dose 95% CI: 0.40-0.65
Early remdesivir tracked with lower graft-loss and cardiovascular hazards
47%lower relative hazard
Compared with no remdesivir, early remdesivir was associated with a 47% lower relative hazard of 1-year all-cause graft loss; 1-year cardiovascular event hazard was also lower.
Adults were kidney transplant recipients with symptomatic COVID-19; remdesivir began within 7 days and was administered for at least 3 consecutive days. Graft loss combined graft failure and all-cause mortality. Results were weight-adjusted; study design is not available in this summary.
No clear difference
Mortality and Long COVID differences remained unclear
Compared with no remdesivir, weighted analyses did not establish lower all-cause mortality or Long COVID risk with early remdesivir.
This concerned adult kidney transplant recipients with symptomatic COVID-19; remdesivir began within 7 days and was administered for at least 3 consecutive days. No clear difference does not prove equivalence; study design is not available in this summary.
Study details & original results
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir initiated within 7 days and administered for at least 3 consecutive days was associated with lower 1-year all-cause graft loss—a composite of graft failure and all-cause mortality—vs no remdesivir after clone-censor-weight adjustment.
HR 0.53 95% CI: 0.31-0.92
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir was associated with lower 1-year cardiovascular event risk vs no remdesivir after clone-censor-weight adjustment.
HR 0.58 95% CI: 0.35-0.98
47% lower relative hazard, calculated from HR 0.53. This is not an absolute percentage-point difference.
Early remdesivir was not significantly associated with lower all-cause mortality among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
HR 0.51 95% CI: 0.24-1.06
Early remdesivir was not significantly associated with lower long-COVID risk among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
HR 0.65 95% CI: 0.21-2.05
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir initiated within 7 days and administered for at least 3 consecutive days was associated with lower 1-year all-cause graft loss—a composite of graft failure and all-cause mortality—vs no remdesivir after clone-censor-weight adjustment.
HR 0.53 95% CI: 0.31-0.92
The reported result does not establish a difference; it does not prove equivalence.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 16 findingsOriginal results, comparisons and study details.
5 of 5 source groupsFindings stay together with their study.
SOURCE 331 finding
Tharmaraj, Dhakshayini et al.. Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.. Internal medicine journal. 2026.
Severe COVID-19 requiring hospitalization among adult kidney transplant recipients during the Delta and Omicron BA.1/BA.2 waves
Added
adjusted HR 0.50 per additional vaccine dose95% CI: 0.40-0.65Source [33]
SOURCE 324 findings
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir initiated within 7 days and administered for at least 3 consecutive days was associated with lower 1-year all-cause graft loss—a composite of graft failure and all-cause mortality—vs no remdesivir after clone-censor-weight adjustment.
Among adult kidney transplant recipients with symptomatic COVID-19, early remdesivir was associated with lower 1-year cardiovascular event risk vs no remdesivir after clone-censor-weight adjustment.
Early remdesivir was not significantly associated with lower all-cause mortality among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
Early remdesivir was not significantly associated with lower long-COVID risk among kidney transplant recipients with symptomatic COVID-19 in the weighted analysis.
Hansrivijit P, Qian C, Boonpheng B, et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020;68(7):1261-1270.
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
Gupta S, Coca SG, Chan L, et al. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161-176.
Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney Int Rep. 2020;5(8):1149-1160.
Hansrivijit P, Qian C, Boonpheng B, et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020;68(7):1261-1270.
Silver SA, Beaubien-Souligny W, Shah PS, et al. The Prevalence of Acute Kidney Injury in Patients Hospitalized With COVID-19 Infection: A Systematic Review and Meta-analysis. Kidney Med. 2021;3(1):83-98.e1.
Farouk SS, Fiaccadori E, Cravedi P, Campbell KN. COVID-19 and the kidney: what we think we know so far and what we don't. J Nephrol. 2020;33(6):1213-1218.
Nugent J, Aklilu A, Engelman ZJ, et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. JAMA Netw Open. 2021;4(3):e211095.
Cravedi P, Mothi SS, Azzi Y, et al. COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140-3148.
ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87-94.
Wysocki J, Ye M, Hassler L, et al. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. J Am Soc Nephrol. 2021;32(4):795-803.
Moledina DG, Simonov M, Yamamoto Y, et al. The Association of COVID-19 with Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. Am J Kidney Dis. 2021;77(4):490-499.e1.
Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial (BRACE-CORONA). JAMA. 2021;325(3):254-264.
American Society of Nephrology. Recommendations on the Care of Hospitalized Patients with COVID-19 and Kidney Failure Requiring Renal Replacement Therapy. 2020.
Original source link unavailable
[25]
Parikh CR, Coca SG. The Long-Term Kidney Consequences of COVID-19. Nat Rev Nephrol. 2022;18(7):417-418.
Batlle D, Soler MJ, Sparks MA, et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J Am Soc Nephrol. 2020;31(7):1380-1383.
Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. 2020;16(10):565-567.
Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med. 2020;180(11):1436-1447.
Choi, Yuni et al.. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2026.
Srisurapanont, Karan et al.. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19.. JAMA network open. 2026.
Tharmaraj, Dhakshayini et al.. Critical role of vaccination in preventing severe coronavirus disease 2019: perspectives from clinical outcomes in an Australian kidney transplant recipient cohort.. Internal medicine journal. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.